, Tracking Stock Market Picks
Enter Symbol:
Avanir Pharmaceuticals (AVNR) [hlAlert]

up 403.26 %

Avanir Pharmaceuticals (AVNR) rated Buy with price target $9 by Canaccord Genuity

Posted on: Thursday,  Oct 7, 2010  11:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Buy Avanir Pharmaceuticals (NASDAQ: AVNR) on 10/07/2010, when the stock price was $3.37. Since
then, Avanir Pharmaceuticals has gained 403.26% as of 01/12/2015's recent price of $16.96.
If you would have followed this Canaccord Genuity's recommendation on AVNR, you would have gained 403.26% of your investment in 1558 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/7/2010 11:25 AM Buy
3.37 9.00
as of 12/31/2010
1 Week down  -2.58 %
1 Month down  -2.58 %
3 Months up  22.84 %
1 YTD up  22.84 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy